ReproCELL Incorporated (4978.T)
JPY 140.0
(1.45%)
JPY 140.0
(1.45%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.05 Billion JPY | 8.34% |
| 2022 | 8.35 Billion JPY | 3.22% |
| 2021 | 8.09 Billion JPY | 33.86% |
| 2020 | 6.04 Billion JPY | -7.71% |
| 2019 | 6.55 Billion JPY | -12.51% |
| 2018 | 7.48 Billion JPY | 13.52% |
| 2017 | 6.59 Billion JPY | -16.0% |
| 2016 | 7.85 Billion JPY | -1.43% |
| 2015 | 7.96 Billion JPY | 4.92% |
| 2014 | 7.59 Billion JPY | 40.15% |
| 2013 | 5.41 Billion JPY | 1234.9% |
| 2012 | 405.92 Million JPY | 28.91% |
| 2011 | 314.89 Million JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 9.16 Billion JPY | 1.29% |
| 2023 Q3 | 8.36 Billion JPY | -0.57% |
| 2023 Q4 | 9.05 Billion JPY | 8.28% |
| 2023 Q1 | 8.45 Billion JPY | 1.15% |
| 2023 Q2 | 8.4 Billion JPY | -0.51% |
| 2023 FY | 9.05 Billion JPY | 8.34% |
| 2022 Q3 | 8.3 Billion JPY | -6.09% |
| 2022 Q1 | 8.19 Billion JPY | 1.2% |
| 2022 FY | 8.35 Billion JPY | 3.22% |
| 2022 Q4 | 8.35 Billion JPY | 0.61% |
| 2022 Q2 | 8.84 Billion JPY | 7.95% |
| 2021 FY | 8.09 Billion JPY | 33.86% |
| 2021 Q1 | 5.87 Billion JPY | -2.79% |
| 2021 Q2 | 6.55 Billion JPY | 11.44% |
| 2021 Q4 | 8.09 Billion JPY | 3.66% |
| 2021 Q3 | 7.8 Billion JPY | 19.2% |
| 2020 Q3 | 6.01 Billion JPY | -4.58% |
| 2020 Q4 | 6.04 Billion JPY | 0.59% |
| 2020 FY | 6.04 Billion JPY | -7.71% |
| 2020 Q1 | 6.39 Billion JPY | -2.46% |
| 2020 Q2 | 6.3 Billion JPY | -1.42% |
| 2019 FY | 6.55 Billion JPY | -12.51% |
| 2019 Q3 | 6.88 Billion JPY | -1.67% |
| 2019 Q4 | 6.55 Billion JPY | -4.8% |
| 2019 Q1 | 7.17 Billion JPY | -4.27% |
| 2019 Q2 | 7 Billion JPY | -2.37% |
| 2018 FY | 7.48 Billion JPY | 13.52% |
| 2018 Q4 | 7.48 Billion JPY | -1.52% |
| 2018 Q3 | 7.6 Billion JPY | -3.15% |
| 2018 Q2 | 7.85 Billion JPY | 18.93% |
| 2018 Q1 | 6.6 Billion JPY | 0.08% |
| 2017 Q3 | 8.21 Billion JPY | -2.45% |
| 2017 FY | 6.59 Billion JPY | -16.0% |
| 2017 Q1 | 8.44 Billion JPY | 7.49% |
| 2017 Q4 | 6.59 Billion JPY | -19.67% |
| 2017 Q2 | 8.41 Billion JPY | -0.27% |
| 2016 FY | 7.85 Billion JPY | -1.43% |
| 2016 Q3 | 7.1 Billion JPY | 0.05% |
| 2016 Q4 | 7.85 Billion JPY | 10.54% |
| 2016 Q2 | 7.1 Billion JPY | -5.49% |
| 2016 Q1 | 7.51 Billion JPY | -5.7% |
| 2015 Q2 | 7.58 Billion JPY | 3.1% |
| 2015 FY | 7.96 Billion JPY | 4.92% |
| 2015 Q1 | 7.35 Billion JPY | -3.15% |
| 2015 Q4 | 7.96 Billion JPY | -13.74% |
| 2015 Q3 | 9.23 Billion JPY | 21.83% |
| 2014 Q3 | 7.69 Billion JPY | 11.1% |
| 2014 Q4 | 7.59 Billion JPY | -1.34% |
| 2014 Q1 | 5.94 Billion JPY | 9.65% |
| 2014 Q2 | 6.92 Billion JPY | 16.61% |
| 2014 FY | 7.59 Billion JPY | 40.15% |
| 2013 FY | 5.41 Billion JPY | 1234.9% |
| 2013 Q1 | 2.32 Billion JPY | 0.0% |
| 2013 Q2 | 2.85 Billion JPY | 22.81% |
| 2013 Q3 | 2.96 Billion JPY | 3.64% |
| 2013 Q4 | 5.41 Billion JPY | 82.94% |
| 2012 FY | 405.92 Million JPY | 28.91% |
| 2011 FY | 314.89 Million JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -37.383% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -647.27% |
| GNI Group Ltd. | 62.39 Billion JPY | 85.491% |
| Linical Co., Ltd. | 18.53 Billion JPY | 51.172% |
| Trans Genic Inc. | 9.81 Billion JPY | 7.73% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -60.674% |
| Soiken Holdings Inc. | 6.94 Billion JPY | -30.326% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -55.641% |
| AnGes, Inc. | 28.89 Billion JPY | 68.668% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -943.801% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 94.241% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -459.294% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -78.508% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -108.112% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -272.099% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -281.425% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | -30.624% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -416.864% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -78.007% |
| PeptiDream Inc. | 67.12 Billion JPY | 86.514% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -343.626% |
| Ribomic Inc. | 3.54 Billion JPY | -155.201% |
| SanBio Company Limited | 5.04 Billion JPY | -79.356% |
| Healios K.K. | 15.15 Billion JPY | 40.266% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -635.832% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -200.153% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -514.089% |
| StemRIM | 9.08 Billion JPY | 0.301% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -31.584% |
| FunPep Company Limited | 2.49 Billion JPY | -263.394% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -245.697% |
| Stella Pharma Corporation | 3.82 Billion JPY | -136.941% |
| TMS Co., Ltd. | 3.55 Billion JPY | -154.663% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -56.648% |
| Cuorips Inc. | 6.18 Billion JPY | -46.37% |
| K Pharma,Inc. | 3.31 Billion JPY | -173.171% |
| Takara Bio Inc. | 123.2 Billion JPY | 92.653% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -233.391% |
| StemCell Institute Inc. | 6.54 Billion JPY | -38.354% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | -29.531% |
| CellSeed Inc. | 2.46 Billion JPY | -267.132% |